Effect of glargine insulin on hyperglycemic control in type II diabetic patients

A clinical trial to compare the effectiveness of glargine insulin and regular insulin in hyperglycemic control among type II diabetic patients undergoing off-pump coronary artery bypass graft surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130428013159N11

Enrollment

Registered

2020-03-14

Start date

2020-04-03

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type II diabetic. Type 2 diabetes mellitus

Interventions

Intervention 1: The intervention group will receive 0.1 mg/kg units/kg glargine insulin 2 hours before the surgery. Based on the Van den Berghe national protocol, regular insulin injection unit is equ

accordingly, each patient will receive 4 units of regular subcutaneous insulin injection for every 40. Intervention 2: Control group: The control group will receive 0.1 cc normal saline 2 hours before

accordingly, each patient will receive 4 units of regular subcutaneous insulin injection for every 40.

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age of 35-75 years Sustaining ASA II Blood sugar of 150-300 mg/dl Lack of a simultaneous emergency surgery or heart valve surgery.

Exclusion criteria

Exclusion criteria: Having underlying diseases (e.g., pulmonary, liver, kidney, thyroid, and digestive diseases) Having history of open-heart surgery Fever Trauma Carotid artery involvement Sensitivity to insulin glargine

Design outcomes

Primary

Measure	Time frame
Blood glucose. Timepoint: Before the surgery, every 2 hours intraoperatively, and every 4-24 hours after the surgery. Method of measurement: Glucose meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Sheybani

Mashhad University of Medical Sciences

Sheybanish@mums.ac.ir+98 51 3840 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026